Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP-Reference-Cited by-同舟云学术

Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP

Published:2022-08-14 Issue:0 Volume:0 Page:0-0
ISSN:0300-0729
Container-title:Rhinology journal
language:
Short-container-title:Rhin

Author:

Bachert C.,Hellings P.W.,Lund V.J.,Fokkens W.J.,Hopkins C.,Mayer B.,Chan R.H.,Smith S.G.,Sousa A.R.,Alfonso-Cristancho R.,Yang S.,on behalf of the SYNAPSE Study Group

Publisher

Stichting Nase

Subject

Otorhinolaryngology,General Medicine

Reference8 articles.

1. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management;Bachert;J Allergy Clin Immunol,2021

2. Understanding the Patient Experience of Severe, Recurrent, Bilateral Nasal Polyps: A Qualitative Interview Study in the United States and Germany;Hall;Value Health,2020

3. 3. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.

4. Adult chronic rhinosinusitis;Bachert;Nat Rev Dis Primers,2020

5. Economics of Chronic Rhinosinusitis;Rudmik;Curr Allergy Asthma Rep,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care;Allergy;2023-12-18

2. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs;Nature Reviews Drug Discovery;2023-08-01

3. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023;Rhinology Journal;2023-03-01